Biocon secures Brazil 10-year Pertuzumab PDP access

What Biocon has signed in Brazil

Biocon Limited has secured a 10-year supply contract in Brazil for Pertuzumab, a monoclonal antibody used to treat HER2-positive breast cancer. The supply arrangement follows a partnership agreement signed with Brazilian public pharmaceutical laboratory Bahiafarma and biotechnology company Bionovis. The arrangement sits under Brazil’s Productive Development Partnership (PDP) framework for oncology medicines. Biocon’s participation is through the Biocon-Bahiafarma-Bionovis consortium. The company said the agreement is aimed at widening access to the therapy while building local manufacturing capability. The contract period is 10 years, aligning with the PDP term. Pertuzumab is referenced as Perjeta, originally associated with Roche.

100% allocation under Brazil’s PDP programme

The consortium has received 100% allocation under Brazil’s 10-year PDP programme for Pertuzumab. This allocation gives the consortium exclusive access to Brazil’s public healthcare market for the drug. The public healthcare channel is significant in Brazil and is stated to account for around 70% of the country’s demand for Pertuzumab. The exclusivity is tied to the PDP structure, which uses state purchasing to support domestic production of key medicines. The arrangement effectively positions the consortium as the sole PDP partner for this molecule in the public market. For Biocon, the allocation matters because it links a long-duration demand channel with a defined government framework. It also provides a route to scale supply through a predictable institutional buyer segment.

How Biocon gets paid: milestones and revenue share

Under the agreement, Biocon will receive milestone payments and a share of revenues generated from the Brazil PDP opportunity over the 10-year period. The article does not specify milestone amounts or the revenue-sharing percentage. What is clear is that the structure combines near-term payments with a long-term participation in sales linked to the public healthcare market. Such structures are typical in technology transfer and localisation programmes where partners are compensated as localisation progresses. The agreement is also framed as expanding access for HER2-positive breast cancer patients. For investors tracking Biocon’s biologics strategy, the detail to watch will be how the phased localisation alters cost, supply responsibilities, and revenue recognition over time. Those specifics were not provided in the disclosed information.

Phased localisation and technology transfer in Brazil

As part of the PDP framework, Pertuzumab will undergo phased localisation in Brazil over the medium to long term. The goal is local production, not only import-led supply. The broader PDP intent is to reduce costs associated with importing complex biological compounds and to secure a steady supply that is less exposed to international market fluctuations and logistics challenges. Bahiafarma, being a Brazilian state-owned public laboratory, is positioned as a key local production participant. Bionovis is part of the consortium alongside Biocon’s Brazil entity, Biocon Biologics do Brasil. The phased nature implies that initial supply may be supported by external manufacturing while capabilities are built locally, though the article does not provide a step-by-step schedule. The localisation element is central to the PDP model and to Brazil’s healthcare procurement approach.

Why the Brazil PDP matters in the India-Brazil context

On 21 February 2026, at the India-Brazil Business Forum in New Delhi, it was announced that Brazil and India entered into three PDPs to leverage state purchasing power and domestically manufacture crucial oncology medicines. The disclosed set of oncology drugs under these arrangements includes biosimilars nivolumab and pertuzumab. These agreements involve Brazilian public institutions and private companies, including Indian companies, and include technology transfer and local production. The Brazilian Ministry of Health estimated its investment could be up to US$140 million in the first year, potentially reaching US$1,900 million over 10 years. Within this broader PDP set, pertuzumab is produced with Bionovis and Biocon Biologics do Brasil, while the nivolumab project involves Bionovis, India’s Dr Reddy’s Laboratories, and Bahiafarma. The context underlines that the pertuzumab PDP is part of a wider push to localise oncology biologics.

Where Pertuzumab sits in Biocon Biologics’ pipeline

The text notes that Biocon Biologics has a pertuzumab biosimilar in its pipeline. It also states that Pertuzumab (Perjeta) was recently submitted to the US FDA. Separately, Biocon Biologics is set to unveil three new biosimilar oncology assets at the 2026 J.P. event: Trastuzumab/Hyaluronidase, Nivolumab, and Pembrolizumab. These are described as among the largest oncology biologics scheduled to lose exclusivity over the next five years. The company’s existing portfolio is described as including 17 oncology medications, with Pertuzumab listed among them. This positioning matters because the Brazil PDP is tied to access and localisation, while the FDA submission and upcoming assets relate to regulated market expansion. Together, they indicate Biocon Biologics is attempting to broaden oncology biologics participation across multiple geographies.

Other partnerships: Eris Lifesciences collaboration in India

Biocon Biologics said it has entered into a long-term commercial collaboration with Eris Lifesciences to expand patient access to its portfolio of Metabolics, Oncology, and Critical Care products in India. The deal is described as a 10-year supply agreement with Eris with a total transaction value of INR 1,242 crore. As part of the transaction, over 430 employees associated with the business are expected to transition to Eris, with continuity highlighted for employees and patients. The terms disclosed include that the transaction value represents an accretive multiple of 3.4x of revenues and 18x of EBITDA. The transaction was expected to come into effect on April 1, 2024, subject to customary closing conditions. The text also notes that the March 2024 collaboration extends the partnership to Biocon’s Metabolics, Oncology and Critical Care portfolios in India.

Australia arrangement: Sandoz promotion rights

Biocon Biologics also disclosed an agreement where Sandoz receives exclusive rights to promote, sell and distribute biosimilars Trastuzumab and Bevacizumab in Australia. The statement frames this as a commercial arrangement focused on market access and distribution. The article does not provide deal value, term, or sales targets for Australia. However, it adds to the pattern of region-specific partnerships to expand commercial reach. The Australia deal also aligns with Biocon Biologics’ oncology focus given the molecules involved. Taken together with Brazil and India, the company is using different routes: PDP localisation in Brazil, business collaboration in India, and distribution partnership in Australia.

Corporate structure update: Biocon and Biocon Biologics

The text states that Biocon said it would fully integrate its biosimilar unit, Biocon Biologics, as a wholly owned subsidiary, consolidating Biocon’s biosimilars and generics businesses under one roof. The dates referenced alongside this update include December 4, 2025 and November 14, 2025. No additional details are provided on the steps, approvals, or financial impact of the integration in the excerpt. Still, the mention is relevant because the Brazil PDP and multiple commercial collaborations are being communicated under the Biocon Biologics identity. Corporate structure clarity can matter when investors assess how revenues, milestone payments, and partnership economics flow within the listed entity.

Key facts at a glance

Conclusion

Biocon’s 10-year Pertuzumab PDP allocation in Brazil places the company in an exclusive public-market supply position tied to localisation and technology transfer. The disclosed payment structure for Biocon includes milestone payments and a share of revenues over the programme period, though key commercial terms remain undisclosed. In parallel, Biocon Biologics continues to broaden partnerships through its India collaboration with Eris Lifesciences and an Australia arrangement with Sandoz for oncology biosimilars. The next set of confirmed reference points in the material are the ongoing phased localisation under the PDP framework and the company’s scheduled disclosures around its oncology biosimilar assets at the 2026 J.P. event.